Immunogenicity of Quadrivalent HPV and Combined Hepatitis A and B Vaccine when Co-administered or Administered One Month Apart to 9-10 Year-old Girls According to 0-6 Month Schedule

Overview

Journal Hum Vaccin Immunother

Specialty Allergy & Immunology

Date 2014 Nov 27

PMID 25424952

Citations 8

Authors

Vladimir Gilca

Chantal Sauvageau

Nicole Boulianne

Gaston De Serres

Michel Couillard

Mel Krajden

Manale Ouakki

Donald Murphy

Andrea Trevisan

Marc Dionne

Affiliations

Soon will be listed here.

Abstract

Background: No immunogenicity data has been reported after a single dose of the quadrivalent HPV vaccine (qHPV-Gardasil®) and no data are available on co-administration of this vaccine with the HAV/HBV vaccine (Twinrix-Junior®). Two pre-licensure studies reported similar anti-HPV but lower anti-HBs titers when co-administering HPV and HBV vaccines.

Objectives: To assess the immunogenicity of the qHPV and HAV/HBV vaccine when co-administered (Group-Co-adm) or given one month apart (Group-Sep) and to measure the persistence of HPV antibodies three years post-second dose of qHPV vaccine in both study groups.

Methods: 416 9-10 year-old girls were enrolled. Vaccination schedule was 0-6 months. Anti-HAV and anti-HBs were measured in all subjects 6 months post-first dose and 1 month post-second dose. Anti-HPV were measured 6 months post-first dose in Group-Co-adm and in all subjects 1 and 36 months post-second dose.

Results: Six months post-first dose: 100% of subjects had detectable anti-HAV and 56% and 73% had detectable anti-HBs in Group-Co-Adm and Group-Sep, respectively. In Group-Co-adm 94, 100, 99 and 96% had detectable antibodies to HPV 6, 11, 16 and 18, respectively. One month post-second dose of qHPV and HAV/HBV vaccine, in both study groups 99.5-100% of subjects had an anti-HAV titer ≥ 20IU/L, 97.5-97.6% an anti-HBs level ≥ 10IU/L, and 100% had an anti-HPV titer ≥ 3LU. Thirty-six months post-second dose of qHPV all but four subjects (99%) had antibodies to HPV18 and 100% had antibodies to HPV6, 11 and 16. The great majority (97-100%) had an anti-HPV titer ≥ 3 LU. Post-second dose administration of qHPV and HAV/HBV, no meaningful difference was observed in the immune response in the two study groups to any component of vaccines.

Conclusions: The results indicate that qHPV and HAV/HBV can be given during the same vaccination session. Two doses of of qHPV and HAV/HBV vaccines induce a strong immune response. Three years post-second dose of qHPV, the great majority of subjects had antibodies to HPV types included in the vaccine. A two-dose schedule for pre-adolescents might be a reasonable alternative to the currently approved three-dose schedules.

Citing Articles

HBV Infection Is an Intermediate-Risk Disease, Whereas Anaemia Is a Mild-to-Moderate Public Health Problem in Young Ghanaian Adults: A Four-Year Retrospective Analysis of Students' Medical Records.

Amoah S, Yartey A, Adjei P, Owusu-Akyaw M, Boachie J, Simpong D Biomed Res Int. 2023; 2023:9318984.

PMID: 37475793 PMC: 10356218. DOI: 10.1155/2023/9318984.

Development and evaluation of a new non-competitive Luminex immunoassay detecting antibodies against human papillomavirus types 6, 11, 16 and 18.

Trevisan A, Wissing M, Dagenais C, Forest P, Ramanakumar A, Burchell A J Gen Virol. 2021; 102(5).

PMID: 34043499 PMC: 8627678. DOI: 10.1099/jgv.0.001610.

Recent Advancement in SARS-CoV-2 Diagnosis, Treatment, and Vaccine Formulation: a New Paradigm of Nanotechnology in Strategic Combating of COVID-19 Pandemic.

Upadhyay S, Dan S, Girdhar M, Rastogi K Curr Pharmacol Rep. 2021; 7(1):1-14.

PMID: 33552875 PMC: 7854874. DOI: 10.1007/s40495-021-00250-z.

Long intervals between two doses of HPV vaccines and magnitude of the immune response: a analysis of two clinical trials.

Gilca V, Sauvageau C, Panicker G, De Serres G, Schiller J, Ouakki M Hum Vaccin Immunother. 2019; 15(7-8):1980-1985.

PMID: 31017850 PMC: 6746485. DOI: 10.1080/21645515.2019.1605278.

Cellular Immune Responses 6 Years Following 1, 2, or 3 Doses of Quadrivalent HPV Vaccine in Fijian Girls and Subsequent Responses to a Dose of Bivalent HPV Vaccine.

Toh Z, Cheow K, Russell F, Hoe E, Reyburn R, Fong J Open Forum Infect Dis. 2018; 5(7):ofy147.

PMID: 30019002 PMC: 6041981. DOI: 10.1093/ofid/ofy147.

References

Van Damme P, van der Wielen M . Combining hepatitis A and B vaccination in children and adolescents. Vaccine. 2001; 19(17-19):2407-12. DOI: 10.1016/s0264-410x(00)00464-3. View

Schwarz T, Spaczynski M, Schneider A, Wysocki J, Galaj A, Schulze K . Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years. Hum Vaccin. 2011; 7(9):958-65. PMC: 3225769. DOI: 10.4161/hv.7.9.15999. View

Yoshikawa H, Ebihara K, Tanaka Y, Noda K . Efficacy of quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine (GARDASIL) in Japanese women aged 18-26 years. Cancer Sci. 2013; 104(4):465-72. PMC: 7657183. DOI: 10.1111/cas.12106. View

Block S, Nolan T, Sattler C, Barr E, Giacoletti K, Marchant C . Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics. 2006; 118(5):2135-45. DOI: 10.1542/peds.2006-0461. View

Scott Lamontagne D, Thiem V, Huong V, Tang Y, Neuzil K . Immunogenicity of quadrivalent HPV vaccine among girls 11 to 13 Years of age vaccinated using alternative dosing schedules: results 29 to 32 months after third dose. J Infect Dis. 2013; 208(8):1325-34. DOI: 10.1093/infdis/jit363. View

Brown B, Blas M, Cabral A, Carcamo C, Gravitt P, Halsey N . Randomized trial of HPV4 vaccine assessing the response to HPV4 vaccine in two schedules among Peruvian female sex workers. Vaccine. 2012; 30(13):2309-14. PMC: 3296898. DOI: 10.1016/j.vaccine.2012.01.058. View

. Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B Immunity. Lancet. 2000; 355(9203):561-5. View

Wolters B, Muller T, Ross R, Clauberg R, Werfel U, Roggendorf H . Comparative evaluation of the immunogenicity of combined hepatitis A and B vaccine by a prospective and retrospective trial. Hum Vaccin. 2009; 5(4):248-53. DOI: 10.4161/hv.5.4.7051. View

Smolen K, Gelinas L, Franzen L, Dobson S, Dawar M, Ogilvie G . Age of recipient and number of doses differentially impact human B and T cell immune memory responses to HPV vaccination. Vaccine. 2012; 30(24):3572-9. DOI: 10.1016/j.vaccine.2012.03.051. View

10.

Wheeler C, Bautista O, Tomassini J, Nelson M, Sattler C, Barr E . Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines. Vaccine. 2008; 26(5):686-96. DOI: 10.1016/j.vaccine.2007.11.043. View

11.

Van Damme P, Leroux-Roels G, Law B, Diaz-Mitoma F, Desombere I, Collard F . Long-term persistence of antibodies induced by vaccination and safety follow-up, with the first combined vaccine against hepatitis A and B in children and adults. J Med Virol. 2001; 65(1):6-13. View

12.

Duval B, Gilca V, Boulianne N, Deceuninck G, Rochette L, De Serres G . Immunogenicity of two paediatric doses of monovalent hepatitis B or combined hepatitis A and B vaccine in 8-10-year-old children. Vaccine. 2005; 23(31):4082-7. DOI: 10.1016/j.vaccine.2004.07.022. View

13.

Krajden M, Cook D, Yu A, Chow R, Su Q, Mei W . Assessment of HPV 16 and HPV 18 antibody responses by pseudovirus neutralization, Merck cLIA and Merck total IgG LIA immunoassays in a reduced dosage quadrivalent HPV vaccine trial. Vaccine. 2013; 32(5):624-30. DOI: 10.1016/j.vaccine.2013.09.007. View

14.

Li R, Li Y, Radley D, Liu Y, Huang T, Sings H . Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, double-blind, placebo-controlled trial in Chinese males and females. Vaccine. 2012; 30(28):4284-91. DOI: 10.1016/j.vaccine.2012.02.079. View

15.

Dobson S, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M . Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA. 2013; 309(17):1793-802. DOI: 10.1001/jama.2013.1625. View

16.

Kreimer A, Rodriguez A, Hildesheim A, Herrero R, Porras C, Schiffman M . Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst. 2011; 103(19):1444-51. PMC: 3186781. DOI: 10.1093/jnci/djr319. View

17.

Bian G, Ma R, Dong H, Ni H, Hu F, Chen Y . Long-term clinical observation of the immunogenicity of inactivated hepatitis A vaccine in children. Vaccine. 2010; 28(30):4798-801. DOI: 10.1016/j.vaccine.2010.04.096. View

18.

Romanowski B, Schwarz T, Ferguson L, Peters K, Dionne M, Schulze K . Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum Vaccin. 2011; 7(12):1374-86. PMC: 3338934. DOI: 10.4161/hv.7.12.18322. View

19.

Einstein M, Baron M, Levin M, Chatterjee A, Fox B, Scholar S . Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years. Hum Vaccin. 2011; 7(12):1343-58. PMC: 3338932. DOI: 10.4161/hv.7.12.18281. View

20.

Gilca V, De Serres G, Boulianne N, Murphy D, Ouakki M, De Wals P . Long-term persistence of immunity after vaccination of pre-adolescents with low doses of a recombinant hepatitis B vaccine. Hum Vaccin Immunother. 2013; 9(8):1685-90. PMC: 3906266. DOI: 10.4161/hv.25015. View